logo
menu

Novozymes delivers strong Q3 results

news item image
In the first nine months of the 2021 financial year, Novozymes delivered 6% organic sales growth, marking an important step in fulfilling its long-term growth strategy.

The global biotechnology company, which has developed methods of boosting efficiency in ethanol production, reported an EBIT-margin of 28.8% and ROIC including goodwill of 22.1%.

“Our results for the first nine months are strong, and I am proud to say that we deliver double-digit organic sales growth in three of our five business areas,” said Ester Baiget, president and CEO of Novozymes.

“Novozymes is built for growth and we are very pleased to upgrade our full-year outlook to 5-6% organic sales growth. We focus on driving our strategy ‘Unlocking Growth – Powered by Biotech’ forward while executing and delivering on our short-term targets.”

Baiget noted there is a growing demand for Novozymes’ biological solutions and the investments it is making now will allow for strong long-term growth and enhanced sustainability impact worldwide.

“We define our priorities among the available opportunities to maximise the return on investments, while always having a clear sustainability mindset in everything we do. Our results so far clearly show that we are headed in the right direction.”